Press Releases
Date picker
Category
Results per page
Kancera enters collaboration with investigators at Northwestern University Feinberg School of Medicine, Chicago, USA, to battle aggressive cancer
In line with Kancera's strategy for the development of new therapies towards cancer, the company enters collaboration with Professor Mary Hendrix and her research group at The Robert H. Lurie…
Full Year Report for Kancera AB (publ)
Regulatory
April 28 – December 31, 2010This Full Year Report relates to Kancera’s first financial year, covering the period April 28 – December 31, 2010. There are thus no historical comparison…
ADDITIONAL INDICATIONS FOR KANCERA LEUKEMIA PROJECT
ROR-1, target for the Kancera treatment for chronic lymphatic leukemia, has been identified on the surface of eight additional blood cancers. Accordingly, medical use of the Kancera candidate drug under…
Kancera acquires iNovacia
Kancera AB (publ) announces that the acquisition of iNovacia AB has been implemented
First day of trade of Kancera AB at the NASDAQ OMX First North will be on February 25th
Regulatory
Kancera AB (publ) ("Kancera") will be admitted to trading on OMX First North. The first trading day will be on Friday, 25 February 2011. The share's short name (ticker) is…
Flagging message
Regulatory
As of 2 February 2011, Kancera AB's future subsidiary iNovacia AB has sold its entire holding of 864,000 shares in Kancera AB at the price of SEK 7 per share.…
Kancera’s new share issue oversubscribed
Regulatory
Kancera AB's new share issue to the public ahead of listing on the NASDAQ OMX First North market was oversubscribed. The new share issue comprised 3,600,000 shares. The issue price…
Kancera announces successful results in structure-based design of candidate molecules against cancer
Kancera AB has in collaboration with Sprint Bioscience AB, Stockholm, solved the 3- dimensional crystal structure of a novel chemical class in complex with the target enzyme PFKFB3, by conducting…
Kancera makes significant progress in pre-clinical drug development against Chronic Leukemia
Kancera AB has discovered compounds that kill Chronic Lymphocytic Leukemia (CLL) 25 times more selectively than cytostatic drugs currently used for treating the disease.
Consolidation within Swedish cancer research
Kancera AB (publ) is carrying out a new share issue, will be listed on First North, and is acquiring the research company iNovacia AB - thereby creating an international and…